Q-omics provides the consensus-scored RANBP6 profile across patient tissues and cancer cell-line models. RANBP6 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RANBP6 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, RANBP6 RNA expression shows 19,750 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, and UVM as cancer lineages where RANBP6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RANBP6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RANBP6 survival associations across molecular data types. RANBP6 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RANBP6 RNA expression–survival associations across cancer types. High RANBP6 expression shows unfavorable associations in UVM and CESC, but favorable associations in KIRC, SKCM, BRCA and LGG. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RANBP6 RNA expression.
This table summarizes RANBP6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for RANBP6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RANBP6 shows lower tumor expression in KIRC, THCA and LUSC and higher tumor expression in COAD, CHOL and LIHC. The KIRC box plot shows higher RANBP6 RNA expression in normal versus tumor tissue (log2 FC = −0.708, t-test p < 0.001).
This table shows molecular features associated with RANBP6 in patient tissues and cancer cell lines. In patient samples, RANBP6 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, RANBP6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BLOOD_Leukemia.
